arimoclomol has been researched along with Disease Exacerbation in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Amato, AA; Barohn, RJ; Blaettler, T; Bonefeld, K; Carstensen, TD; Ciafaloni, E; Dimachkie, MM; Freimer, M; Gibson, SB; Hanna, MG; Heim, AJ; Herbelin, L; Jones, SM; Jørgensen, AN; Levine, TD; Lloyd, TE; Machado, PM; McDermott, MP; Mozaffar, T; Phonekeo, K; Rosholm, A; Shaibani, AI; Sundgreen, C; Wicklund, M | 1 |
| Andreasen, AK; Blaettler, T; Da Riol, RM; Day, S; Del Toro, M; Deodato, F; Gautschi, M; Geist, MA; Grunewald, S; Grønborg, S; Hansen, T; Harmatz, P; Havnsøe Torp Petersen, N; Héron, B; Í Dali, C; Ingemann, L; Kirkegaard, T; Maier, EM; Mengel, E; Patterson, MC; Roubertie, A; Santra, S; Tylki-Szymanska, A | 1 |
| Andersen, PM; Atassi, N; Benatar, M; Cudkowicz, M; David, W; Schoenfeld, D; Wuu, J | 1 |
| Arenz, C; Atkins, J; Begley, D; Bornæs, C; Drndarski, S; Gray, J; Hinsby, A; Ingemann, L; Jäättelä, M; Jørgensen, SH; Kirkegaard, T; Klein, A; Morris, L; Olsen, OD; Petersen, NH; Platt, FM; Priestman, DA; Smith, DA; Wallom, KL; Williams, I | 1 |
| Cheetham, ME; Gray, A; Greensmith, L; Kalmar, B; Margulis, B; Novoselov, S | 1 |
| Edet-Amana, E; Greensmith, L; Kalmar, B | 1 |
| Dick, J; Greensmith, L; Kalmar, B; Lu, CH; Malaspina, A; Petzold, A | 1 |
| Gray, AL; Greensmith, L; Hanna, MG; La Spada, AR; Malik, B; Nirmalananthan, N | 1 |
| Burnstock, G; Dick, JR; Greensmith, L; Kalmar, B; Kieran, D; Riddoch-Contreras, J | 1 |
3 trial(s) available for arimoclomol and Disease Exacerbation
| Article | Year |
|---|---|
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Animals; Disease Progression; Double-Blind Method; Female; Humans; Male; Mice; Myositis, Inclusion Body; Pilot Projects; United States | 2023 |
Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment.
Topics: Adolescent; Child; Child, Preschool; Disease Progression; Double-Blind Method; Female; Humans; Hydroxylamines; Internationality; Male; Niemann-Pick Disease, Type C; Prospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2021 |
Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Female; Humans; Hydroxylamines; Male; Middle Aged; Neuroprotective Agents; Severity of Illness Index; Superoxide Dismutase-1; Survival Analysis; Treatment Outcome | 2018 |
6 other study(ies) available for arimoclomol and Disease Exacerbation
| Article | Year |
|---|---|
Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses.
Topics: Administration, Intravenous; Animals; Blood-Brain Barrier; Bone Morphogenetic Proteins; Disease Models, Animal; Disease Progression; Fabry Disease; Fibroblasts; Glycosphingolipids; Heat-Shock Proteins; Humans; Hydroxylamines; Injections, Intraperitoneal; Intracellular Signaling Peptides and Proteins; Lysosomes; Niemann-Pick C1 Protein; Niemann-Pick Disease, Type C; Proteins; Recombinant Proteins; Sphingolipidoses; Tissue Distribution | 2016 |
Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS.
Topics: Age Factors; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Disease Progression; Female; HSP70 Heat-Shock Proteins; Humans; Hydroxylamines; Male; Mice; Mice, Transgenic; Motor Neurons; Muscle, Skeletal; Spinal Cord; Statistics, Nonparametric; Superoxide Dismutase; Survival Analysis; Ubiquitin | 2008 |
Treatment with a coinducer of the heat shock response delays muscle denervation in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.
Topics: Acetylcholinesterase; Amyotrophic Lateral Sclerosis; Animals; Choline O-Acetyltransferase; Disease Models, Animal; Disease Progression; GPI-Linked Proteins; Heat-Shock Response; HSP70 Heat-Shock Proteins; Hydroxylamines; Longitudinal Studies; Mice; Mice, Transgenic; Motor Neurons; Muscle Fibers, Fast-Twitch; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; Neuromuscular Junction; Succinate Dehydrogenase; Superoxide Dismutase | 2012 |
Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS.
Topics: Amyotrophic Lateral Sclerosis; Animals; Biomarkers; Disease Models, Animal; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Hydroxylamines; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscles; Neurofilament Proteins; Phosphorylation; Spinal Cord; Superoxide Dismutase; Superoxide Dismutase-1; Treatment Outcome | 2012 |
Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy.
Topics: Animals; Blotting, Western; Disease Models, Animal; Disease Progression; Heat-Shock Proteins; Heat-Shock Response; Hydroxylamines; Male; Mice; Muscular Disorders, Atrophic; Neuroprotective Agents; Real-Time Polymerase Chain Reaction | 2013 |
Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice.
Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Progression; Heat-Shock Proteins; Humans; Hydroxylamines; Mice; Mice, Transgenic; Motor Neurons; Mutation; Superoxide Dismutase | 2004 |